p53 Pathway Inactivation Drives SMARCB1-deficient p53-wildtype Epithelioid Sarcoma Onset Indicating Therapeutic Vulnerability Through MDM2 Inhibition.

Oppel F, Shao S, Gendreizig S, Zimmerman MW, Schurmann M, Flavian VF, Goon P, Chi SN, Aster JC, Sudhoff H, Look AT
Mol Cancer Ther. 2022 Nov 3;21(11):1689-1700. doi: 10.1158/1535-7163.MCT-21-0770. PubMed Article

Plasmids from Article

No plasmids are currently publicly available from Addgene for this article.